Finally...

Biocryst Pharmaceuticals finally receives Emergency Use Authorization from the FDA for Peramivir, the intravenously-applied anti-viral for the novel H1N1 flu virus.

http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=417887

Now doctors can get down to the business of saving lives for patients with severe cases of the swine flu.

Expect orders domestically and abroad.

Disclosure: long BCRX shares.